Market Newsdesk

ADS-TEC Energy Establishes First North American Site for Its Ultra-Fast Charging Technology in Auburn, Alabama

• ADS-TEC Energy to invest $8 million dollars in sales, warehousing, service and assembly facility, creating approximately 180 jobs
• Alabama Governor Kay Ivey supports ADS-TEC Energy and facilitates grants
• ADS-TEC Energy will produce battery-backed ultra-fast charging solutions for e-vehicles in the U.S. market

NÜRTINGEN, Germany & AUBURN, Ala.–(BUSINESS WIRE)–ADS-TEC Energy (NASDAQ: ADSE), a leader in battery-buffered, ultra-fast-charging solutions, today announced it is establishing its first dedicated facility in North America in Auburn, Ala., bringing together sales, warehousing, service and assembly in the new location. The company expects its new site in the United States to be fully functional by 2024, expanding ADS-TEC Energy’s manufacturing to include both Germany and the U.S. ADS-TEC Energy plans invest $8 million and create approximately 180 jobs in the coming years associated with the new site, which will facilitate the expansion of e-vehicle charging infrastructure in the U.S.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005517/en/

“We’re excited to welcome yet another high-tech German company to Alabama,” Governor Kay Ivey said. “The partnership between German engineering and Alabama manufacturing has brought many innovative products to the North American market. We’re excited to add ADS-TEC Energy’s battery-buffered fast charging stations to that list, serving the quickly growing electric vehicle market.”

“The City of Auburn is grateful for the trust that Thomas Speidel and his team have in our community, and we will do everything we can to support ADS-TEC Energy in establishing a successful operation in Auburn,” Mayor Ron Anders said. “The assembling and servicing of innovative equipment for the emerging electric charging infrastructure market right here in Auburn will create well-paying and clean high-tech jobs for Auburn residents.”

Auburn, Ala.– important business location in the U.S.

Auburn, Ala. is an important business location in the U.S. Among others, companies from the aerospace sector are located there, including Airbus and NASA. Automotive leader Mercedes-Benz has been based in Auburn since 1993, followed by Honda, Hyundai and Toyota. It is also home to many small- and mid-sized, technology-based, value-added manufacturing companies in the automotive, distribution and technology-based industries. Auburn University is a training ground for talented professionals. The crew for NASA’s current Artemis I lunar mission includes numerous Auburn University alumni. ADS-TEC intends to develop a cooperative program with Auburn University, providing students and new graduates with positions in production and management. It will also cooperate with Alabama-based companies, wherever possible.

ADS-TEC Energy ultra-fast charging systems – powerful, reliable and optimum TCO

With its ChargeBox and ChargePost systems, ADS-TEC has developed powerful, reliable technologies with an optimal long-term total cost of ownership (TCO). Both systems can be installed quickly and easily—connected to the existing, limited-power electrical grid, without requiring any expansion of the network—and offer the industry’s highest rates of ultra-fast charging. The company’s latest ultra-fast charging solution, ChargePost, integrates two charging dispensers that combine power electronics, battery storage and air conditioning with up to two 75-inch displays in an extremely powerful, compact and quiet “all-in-one” system. ChargePost is available currently in Europe and will soon be available in the U.S.

ADS-TEC Energy Founder and CEO Thomas Speidel said, “We are very pleased to announce significant progress in the U.S. Having been listed on NASDAQ for less than a year, we already have a successful market presence in the Americas, and now are establishing a new location for sales, warehousing, service and assembly of our fast-charging systems in Auburn, supported by a strong economic environment driven by innovation and growth. We are very grateful for the intensive support of the local economic development agency and the State of Alabama, especially Governor Kay Ivey, and the open doors of the local decision-makers, who have given us constructive support. ADS-TEC is ‘Engineered in Germany,’ and we are proud to extend our quality products to the U.S.,” he added.

ADS-TEC Energy’s charging technology was nominated for the German Future Prize in 2022 by the President of the Federal Republic of Germany and elevated to the “circle of excellence.”

About ADS-TEC Energy

ADS-TEC Energy plc, a public limited company incorporated in Ireland and publicly listed on NASDAQ (“ADS-TEC Energy”), serves as a holding company for ads-tec Energy GmbH, our operating company incorporated in Germany (“ADSE GM”) and ads-tec Energy Inc., a US subsidiary of ads-tec Energy GmbH (“ADSE US” and together with ADS-TEC Energy and ADSE GM, “ADSE”). Based on more than ten years of experience with lithium-ion technologies, ADS-TEC Energy develops and manufactures battery storage solutions and fast charging systems including their energy management systems. Its battery-based, fast charging technology enables electric vehicles to ultrafast charge even on low powered grids and features a very compact design. The high quality and functionality of the battery systems are due to a particularly high depth of development and in-house production. With its advanced system platforms, ADS-TEC Energy is a valuable partner for automotive, OEMs, utility companies and charge-operators.

More information: www.adstec-energy.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements regarding our expectations with respect to future performance and the anticipated timing of certain commercial activities, such as the Company’s plans to invest $8 million and create about 180 jobs over the next two years, the Company’s timeline for the Auburn technology site to reach full capacity, the Company’s plans to make charging stations available in each state in the U.S. and the availability of the ChargePost in the U.S. in the future. There are a significant number of factors that could cause actual results to differ materially from the statements made in this press release, including: the impact of the COVID-19 pandemic, geopolitical events including the Russian invasion of Ukraine, macroeconomic trends including changes in inflation or interest rates, or other events beyond our control on the overall economy, our business and those of our customers and suppliers, including due to supply chain disruptions and expense increases; our limited operating history as a public company; our dependence on widespread acceptance and adoption of EVs and increased installation of charging stations; our current dependence on sales to a limited number of customers for most of our revenues; overall demand for EV charging and the potential for reduced demand for EVs if governmental rebates, tax credits and other financial incentives are reduced, modified or eliminated or governmental mandates to increase the use of EVs or decrease the use of vehicles powered by fossil fuels, either directly or indirectly through mandated limits on carbon emissions, are reduced, modified or eliminated; supply chain interruptions and expense increases; unexpected delays in new product introductions; our ability to expand our operations and market share in Europe and the U.S.; the effects of competition; changes to battery energy storage standards; and the risk that our technology could have undetected defects or errors. Additional risks and uncertainties that could affect our financial results are included under “Item 3. Key Information – 3.D. Risk Factors” in our annual report on Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2022, which is available on our website at https://adstec-energy.com/corporate-governance/ and on the SEC’s website at www.sec.gov. Additional information will also be set forth in other filings that we make with the SEC from time to time. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005517/en/

Media:

For ADS-TEC Energy – Germany

Dennis Müller

SVP Product Marketing & Communication

[email protected]

For ADS-TEC Energy – US

Barbara Hagin

Breakaway Communications

+1 408-832-7626

[email protected]

Scott Gamm

Strategy Voice Associates

+1 917-626-9515

[email protected]

KEYWORDS: Germany Europe United States North America Alabama

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Technology EV/Electric Vehicles Vehicle Technology Automotive General Automotive Other Automotive Alternative Energy Energy Batteries

MEDIA:

Logo

Photo

ADS-TEC Energy, a leader in battery-buffered, ultra-fast-charging solutions, today announced it is establishing its first dedicated facility in North America in Auburn, Ala., bringing together sales, warehousing, service and assembly in the new location. (Photo: Business Wire)

Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2023. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2022 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.

You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada. The passcode is “51512”.

The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice:The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities; and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our efforts to respond to COVID-19, including our COVID-19 products; our expectations regarding the impact of COVID-19 on our business, operations and financial results; and other statements about our business, operations and financial results, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Category: Finance

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005212/en/

Media:

[email protected]

+1 (212) 733-1226

Investors:

[email protected]

+1 (212) 733-4848

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo

Motorola Solutions’ FIPS-Compliant Avigilon Video Security Solutions Certified by Joint Interoperability Test Command for the Department of Defense

Certification signifies the solutions meet specific criteria to help federal and defense agencies globally protect facilities, bases and personnel from security threats

CHICAGO–(BUSINESS WIRE)–
Motorola Solutions (NYSE: MSI) today announced it has received Joint Interoperability Test Command (JITC) certification from the U.S. Defense Information Systems Agency (DISA) for its Federal Information Processing Standards (FIPS)-compliant Avigilon video security solutions. Motorola Solutions’ Avigilon Control Center (software release version 7) and H5A Series cameras have gone through rigorous interoperability testing from a JITC lab approved by the Department of Defense (DoD).

JITC provides risk based test, evaluation and certification services, tools and environments to ensure DoD information technology capabilities are interoperable and support mission needs.

“We’re proud to support our defense and federal customers, dedicated to protecting our national security,” said Joe Balchune, vice president Federal Markets, Motorola Solutions. “JITC certification from DISA highlights Motorola Solutions’ commitment to supporting our customers with security solutions that meet exacting criteria and can be trusted to help protect their operations.”

Motorola Solutions’ Avigilon cameras allow our customers to be National Defense Authorization Act (NDAA) Sec. 889 compliant.

About Motorola Solutions

Motorola Solutions is a global leader in public safety and enterprise security. Our solutions in land mobile radio communications, video security & access control and command center software, bolstered by managed & support services, create an integrated technology ecosystem to help make communities safer and businesses stay productive and secure. At Motorola Solutions, we’re ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005103/en/

Kathy Van Buskirk

Motorola Solutions

Mobile: 720.771.7651

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Technology Mobile/Wireless Audio/Video Homeland Security Law Enforcement/Emergency Services Public Policy/Government Defense Other Technology Telecommunications Other Defense Networks Hardware Security Government Technology

MEDIA:

Logo

WPP invests in new Atlanta Campus

NEW YORK–(BUSINESS WIRE)–
WPP (NYSE: WPP) will create a world-class workspace for its people in Atlanta’s historic Old Fourth Ward neighborhood with the development of a new Campus.

The Campus will bring together over 400 of WPP’s people in the largest and most transformative new mixed-use development on the Atlanta BeltLine to date. It will house ten agencies based in the city including AKQA, BCW, EssenceMediacom, GCI Health, GroupM, GTB, Mindshare, Verticurl, VMLY&R and Wunderman Thompson.

The WPP Campus in Atlanta will feature an imaginative blend of public and private spaces that will seamlessly integrate into an already thriving community. The close proximity to The Coca-Cola Company’s headquarters and WPP’s other clients in the heart of Georgia’s capital city will foster greater collaboration via dedicated client spaces and continued growth of OpenX from WPP, the bespoke agency created in 2021 following WPP’s appointment as The Coca-Cola Company’s Global Marketing Network Partner. The Campus will also act as a unique new hub for Atlanta’s thriving technology scene.

WPP will lease office space from renowned real estate development firm New City in Tower 2 of the new Fourth Ward offices, neighboring the Historic Fourth Ward Park and Ponce City Market. The office design draws on inspiration from world-class architecture and boasts amenities including a 39,000-square-foot conference center, dozens of walkable shops and restaurants, and convenient access to the BeltLine.

The Atlanta Campus will target a “Gold” LEED rating, and WPP-owned BDG architecture + design will assist with the design of the interior office space. The Atlanta Campus will be WPP’s sixth in North America and the first to be unveiled in the U.S. this year. The move is set to be completed in the second quarter of 2023.

Michael Houston, President of WPP in the US, said: “We are thrilled to provide a new Campus for our agencies in the Atlanta community, especially in the Old Fourth Ward neighborhood which is experiencing unprecedented growth and transformation. Between the interface with the BeltLine and the surrounding amenities, the Atlanta Campus fosters the type of creative environment that will inspire our people, clients and partners alike.”

Jim Irwin, President of New City, said: “We are thrilled and humbled that WPP has selected the Fourth Ward Project for their Atlanta Headquarters. When we first began work on the master plan, we envisioned it as a place for best-in-class companies, like WPP, to cater to the evolving needs of their workforce and clients.”

About WPP

WPP is the creative transformation company. We use the power of creativity to build better futures for our people, planet, clients and communities. For more information, visit www.wpp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005808/en/

Martina Suess, WPP

+1 917-456-5049

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo

Partnership Allows 1Retail POS Systems to Store Card Information for Future Purchases

Florida Office of Insurance Regulation Approves East Resources Acquisition Company’s Business Combination With Abacus Life

ORLANDO, Fla. & BOCA RATON, Fla.–(BUSINESS WIRE)–
Abacus Settlements, LLC (d/b/a Abacus Life) and Longevity Market Assets, LLC (together “Abacus”), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, announced today that the Florida Office of Insurance Regulation executed a consent order approving East Resources Acquisition Company’s (NASDAQ: ERES) (“East Resources” or “ERES”) business combination with Abacus.

“The Florida Office of Insurance Regulation’s approval of our business combination with East Resources Acquisition Company is a critical step in the transaction process and is an important step for our team to execute its strategy to scale our platform and increase our market share of the growing $233 billion potential Annual Life Settlement market,” said Abacus Life CEO Jay Jackson.

As previously announced, on August 30, 2022, Abacus Life entered into a definitive merger agreement with East Resources, a special purpose acquisition company, that is expected to result in Abacus Life becoming a publicly listed company. Completion of the business combination is subject to customary closing conditions.

Abacus Life’s team of 61 experienced professionals, which has serviced approximately $950

million in policies since October 2021 and is operational in 49 states, provides white-glove service to financial advisors and policy owners who need to value life insurance policies and explore this lucrative financial option.

Abacus Life is a BBB Accredited Business with an A+ rating.

About Abacus

Abacus is a leading vertically integrated alternative asset manager specializing in life insurance products. Since 2004, the company has purchased life insurance policies from consumers seeking liquidity and has actively managed those policies over time (via trading, holding, and/or servicing). With over $2.9 billion in face value of policies purchased, Abacus has helped thousands of clients maximize the value of life insurance.

Over the past 18 years, the company has built an institutionalized origination and portfolio management process that is supported by a 61-person team, long-term relationships with 78 institutional partners and 30,000 financial advisors, and the ability to operate in 49 states. The company has serviced approximately $950 million in policies since October 2021 and has managed assets for large asset managers and third-party investment funds.

Abacus’ leadership team averages 20+ years of experience and have been innovators since the life settlements industry’s inception in the mid-90s.

The company is a proud member of the Life Insurance Settlements Association (LISA) and complies with HIPAA and privacy laws to maintain and protect confidentiality of financial, health, and medical information. Abacus is also proud to be a BBB Accredited Business with an A+ rating.

www.Abacuslife.com

About East Resources Acquisition Company

East Resources Acquisition Company, led by Terrence (Terry) M. Pegula, is a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in North America.

Forward-Looking Statements

This communication contains certain forward-looking statements within the meaning of the federal securities laws with respect to the transaction, including statements regarding the anticipated benefits of the transaction, the anticipated timing of the transaction, the future financial condition and performance of Abacus and expected financial impacts of the transaction (including future revenue and pro forma enterprise value) and the platform and markets and expected future growth and market opportunities of Abacus. These forward-looking statements generally are identified by the words “believe,” “predict,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “scales,” “representative of,” “valuation,” “potential,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these terms or variations of them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are inherently subject to risks and uncertainties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond ERES’s or Abacus’s control, are difficult or impossible to predict and may differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ERES’s securities, (ii) the risk that the transaction may not be completed by ERES’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by ERES, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the requisite approvals of ERES’s stockholders and Abacus’s owners, the satisfaction of the minimum aggregate transaction proceeds amount following any redemptions by ERES’s public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement relating to the transaction, (vi) the effect of the announcement or pendency of the transaction on Abacus’s business or employee relationships, operating results and business generally, (vii) the risk that the transaction disrupts current plans and operations of Abacus, (viii) the risk of difficulties in retaining employees of Abacus as a result of the transaction, (ix) the outcome of any legal proceedings that may be instituted against Abacus or against ERES related to the merger agreement or the transaction, (x) the ability to maintain the listing of ERES’s securities on a national securities exchange, (xi) changes in the competitive industries in which Abacus operate, variations in operating performance across competitors, changes in laws and regulations affecting Abacus’s business and changes in the combined capital structure, (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the transaction, and the ability to identify and realize additional opportunities, (xiii) risks related to the uncertainty of Abacus’s projected financial information, (xiv) current and future conditions in the global economy, including as a result of the impact of the COVID-19 pandemic, (xv) the risk that demand for Abacus’s life settlement and related offerings does not grow as expected, (xvi) the ability of Abacus to retain existing customers and attract new customers, (xvii) the potential inability of Abacus to manage growth effectively, (xviii) the potential inability of Abacus to grow its market share of the life settlement industry or to achieve efficiencies regarding its operating model or other costs, (xix) negative trends in the life settlement industry impacting the value of life settlements, including increases to the premium costs of life insurance policies, increased longevity of insureds, and errors in the methodology and assumptions of life expectancy reports, (xx) legal challenges by insurers relating to the validity of the origination or assignment of certain life settlements, (xxi) the enforceability of Abacus’s intellectual property rights, including its trademarks and trade secrets, and the potential infringement on the intellectual property rights of others, (xxii) Abacus’s dependence on senior management and other key employees, (xxiii) the risk of downturns and a changing regulatory landscape in the industry in which Abacus operates, and (xxiv) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions. The foregoing list of factors is not exhaustive.

Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should carefully consider the foregoing factors and the other risks and uncertainties which will be more fully described in the “Risk Factors” section of the proxy statement discussed below and other documents filed by ERES from time to time with the Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers of this communication are cautioned not to put undue reliance on forward-looking statements, and Abacus and ERES assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Abacus nor ERES gives any assurance that any of Abacus or ERES, or the combined company, will achieve expectations.

Additional Information About the Proposed Transaction and Where to Find It

This communication relates to the proposed transaction between ERES and Abacus. In connection with the proposed transaction, ERES has filed with the SEC a preliminary proxy statement on Schedule 14A (the “proxy statement”). ERES will also file other documents regarding the transaction with the SEC. Before making any voting decision, investors, security holders and other interested persons of ERES and Abacus are urged to read the proxy statement (including all amendments and supplements thereto), which is currently available, and all other relevant documents filed or that will be filed with the SEC in connection with the transaction as they become available because they will contain important information about the transaction. Investors, security holders and other interested persons will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed with the SEC by ERES through the website maintained by the SEC at www.sec.gov. The documents filed by ERES with the SEC also may be obtained free of charge upon written request to ERES at 7777 NW Beacon Square Boulevard, Boca Raton, Florida 33487.

Participants in the Solicitation

ERES, Abacus and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ERES stockholders in connection with the transaction. A list of the names of such directors and executive officers and information regarding their interests in the transaction are or will be contained in the proxy statement. You can find more information about ERES’s directors and executive officers in ERES’s Annual Report on Form 10-K for the year ended December 31, 2021, which ERES filed with the SEC on June 22, 2022. You may obtain free copies of these documents as described in the preceding paragraph.

No Offer or Solicitation

This communication does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, sale, or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act, or an exemption therefrom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005507/en/

East Resources Acquisition Company

Investor Contact: Kelly Seward

[email protected]

Abacus Life Investor Relations

[email protected]

Abacus Life Public Relations

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Insurance Finance

MEDIA:

Posted on December 20, 2022 10:45 am

NIO Inc. Promptly Responds to Data Leakage

SHANGHAI, China, Dec. 20, 2022 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today issued this press release in response to a recent incident related to NIO’s data security.

On December 20, 2022, the Company was made aware that certain information of users and vehicle sales in China before August 2021 were sold on the internet by third parties for illegal purposes.

NIO has issued a public statement in China related to the incident, including providing a dedicated hotline and an email address to respond to users’ queries regarding the data leakage. The Company has also undertaken the responsibilities for the loss that the users may incur in connection with the data leakage.

NIO deeply regrets this incident happened, and is doing everything possible to support its users. NIO continues to work with governmental authorities to investigate the incident and implement necessary measures to contain potential damages. NIO reaffirms its commitment to protecting data security and privacy of its users.

About NIO Inc.

NIO Inc. is a pioneer and a leading company in the premium smart electric vehicle market. Founded in November 2014, NIO’s mission is to shape a joyful lifestyle. NIO aims to build a community starting with smart electric vehicles to share joy and grow together with users. NIO designs, develops, jointly manufactures and sells premium smart electric vehicles, driving innovations in next-generation technologies in autonomous driving, digital technologies, electric powertrains and batteries. NIO differentiates itself through its continuous technological breakthroughs and innovations, such as its industry-leading battery swapping technologies, Battery as a Service, or BaaS, as well as its proprietary autonomous driving technologies and Autonomous Driving as a Service, or ADaaS. NIO’s product portfolio consists of the ES8, a six- or seven-seater flagship premium smart electric SUV, the ES7 (or the EL7), a mid-large five-seater premium smart electric SUV, the ES6, a five-seater high-performance premium smart electric SUV, the EC6, a five-seater premium smart electric coupe SUV, the ET7, a flagship premium smart electric sedan, and the ET5, a mid-size premium smart electric sedan.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. NIO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in announcements, circulars or other publications made on the websites of each of The Stock Exchange of Hong Kong Limited (the “SEHK”) and the Singapore Exchange Securities Trading Limited (the “SGX-ST”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIO’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIO’s strategies; NIO’s future business development, financial condition and results of operations; NIO’s ability to develop and manufacture a car of sufficient quality and appeal to customers on schedule and on a large scale; its ability to ensure and expand manufacturing capacities including establishing and maintaining partnerships with third parties; its ability to provide convenient and comprehensive power solutions to its customers; the viability, growth potential and prospects of the newly introduced BaaS and ADaaS; its ability to improve the technologies or develop alternative technologies in meeting evolving market demand and industry development; NIO’s ability to satisfy the mandated safety standards relating to motor vehicles; its ability to secure supply of raw materials or other components used in its vehicles; its ability to secure sufficient reservations and sales of the ES8, ES7 (or the EL7), ES6, EC6, ET7 and ET5; its ability to control costs associated with its operations; its ability to build the NIO brand; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIO’s filings with the U.S. Securities and Exchange Commission and the announcements and filings on the websites of each of the SEHK and SGX-ST. All information provided in this press release is as of the date of this press release, and NIO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please visit: http://ir.nio.com

Investor Relations

[email protected]

Media Relations

[email protected]

Posted on December 20, 2022 10:44 am

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

• Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine effects on clinically important secondary endpoints
  
• Qualitative and quantitative primary market research conducted post-SUMMIT trial readout and incorporating updated STS101 profile consistent with SUMMIT trial results indicates headache specialists continue to have strong interest in STS101, with high prescribers of migraine therapeutics anticipating prescribing it to approximately 30% of their migraine patients
• Based on communications with FDA in multiple Type C meetings and May 2022 Type B clinical pre-NDA meeting, and discussions with legal-regulatory consultants, Satsuma believes the results of its STS101 clinical trial program support planned NDA filing in Q1 2023 and potential approval  
• Based on input from expert legal-regulatory and statistical consultants, Satsuma believes there is a compelling rationale, with regulatory precedents, for including a portion of the SUMMIT trial efficacy results in the STS101 prescribing information, despite STS101 not achieving statistical significance (p<0.05) versus placebo on study co-primary endpoints at the primary timepoint of two hours post-treatment
• Commercial manufacturing capability established to support NDA filing, potential approval and subsequent product launch
• Satsuma is working to secure a commercialization partner for STS101

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today provided an update on its STS101 development program and corporate update.

SUMMIT Phase 3 efficacy trial recap

Recapping results from the STS101 SUMMIT Phase 3 efficacy trial, the largest-ever clinical trial conducted with any DHE product:

• High proportions of subjects’ treated migraine attacks had symptoms predictive of poor response to treatment.
• STS101 demonstrated numerical but not statistically significant differences versus placebo on the study co-primary endpoints (% of subjects free from pain and % of subjects free from most-bothersome-symptom (MBS)¹ at two hours post-dose.)
• STS101 demonstrated robust and sustained effects (p<0.001) on the key study endpoints, freedom from pain and freedom from MBS, at all post-dose timepoints after 2 hours (3, 4, 6, 12, 24 and 48 hours).
• As detailed below, STS101 demonstrated robust and sustained antimigraine effects across numerous secondary endpoints considered clinically relevant and recommended for assessment in efficacy trials by the U.S. Food and Drug Administration (FDA) in its current industry guidance document and/or the International Headache Society’s guidelines for controlled trials of acute treatment of migraine attacks.^2,3

Endpoint	Time (post-dose)	p-value (nominal)*
Pain relief	All timepoints 2 – 48h	<0.002
Sustained freedom from pain	2 – 24h	0.0470
No use of rescue medication	within 24h and 48h	<0.0001
Freedom from photophobia	all timepoints 3 – 48h	≤0.01
Freedom from phonophobia	all timepoints 3 – 48h	≤0.02
Freedom from nausea	all timepoints 3 – 48h	≤0.01
Time to pain freedom	-na-	<0.0001
Time to MBS freedom	-na-	<0.0001
Total Migraine Freedom**	all timepoints 3 – 48h	≤0.014
Return to normal function	all timepoints 4*** – 48h	≤0.001
*     For endpoints evaluated at multiple timepoints, listed p-values are the highest of any timepoint in range
**   Total Migraine Freedom defined as freedom from pain, photophobia, phonophobia and nausea
***  Return to normal function assessed at only at 1, 2, 4, 24 and 48h timepoints

• In addition, STS101 demonstrated efficacy in subjects who experienced common and difficult-to-treat migraine attack types, including migraine with allodynia and menstrually-associated migraine.
• Consistent with clinical trial experience to date in subjects who have administered more than 10,000 doses of STS101 to treat their migraine attacks, STS101 demonstrated a favorable safety and tolerability profile in SUMMIT. The only treatment-emergent adverse event reported by more than 5% of SUMMIT subjects who self-administered STS101 was nasal discomfort, reported by 8.3% and 1.5% of subjects who self-administered STS101 and placebo, respectively. No treatment-related serious adverse events or cardiovascular events occurred.

STS101 demonstrates differentiated profile with primary market research conducted post-SUMMIT trial readout indicating potential for broad use

The Company believes STS101 has the potential to address the unmet needs of many of the ~40 million people with migraine in the U.S. given its differentiated profile characterized by (i) demonstration of robust and sustained single-dose antimigraine effects in a large, randomized, placebo-controlled clinical trial; (ii) elegant simplicity and ease-of-use; and (iii) favorable safety and tolerability. Qualitative and quantitative primary market research with headache specialists and prescribers of migraine therapeutics undertaken by Satsuma following announcement of SUMMIT trial results, and which utilized an updated STS101 product profile incorporating SUMMIT trial results, indicate physicians view STS101 as having broad potential therapeutic utility across a variety of migraine patient- and attack types. Interviewed and surveyed physicians expressed strong interest in prescribing STS101 for a broad range of migraine patient and migraine attack types, with surveyed physicians indicating intent to prescribe STS101 for approximately 30% of their patients with migraine⁴. The results of this primary market research are consistent with previous market research conducted by Satsuma indicating that physicians’ strong interest in and intent to prescribe STS101 was minimally dependent on the magnitude of effect size demonstrated by STS101 against co-primary endpoints at two hours post-dosing in a Phase 3 efficacy trial, and rather was driven by the unique overall profile and attributes of STS101.

Clear near-term path to regulatory approval with compelling rationale for inclusion of SUMMIT trial efficacy results in STS101 prescribing information

Based on its communications with FDA in multiple Type C meetings and the May 2022 Type B clinical pre-NDA meeting, Satsuma believes the results of its STS101 clinical trial program, and in particular results from the Phase 1 comparative PK study completed in 2021 and the on-going ASCEND long-term, open-label safety trial, support a planned NDA filing in Q1 2023 and potential approval. In addition, based on input from expert legal-regulatory and statistical consultants, Satsuma believes there is a compelling rationale, with regulatory precedents, for including a portion of the SUMMIT trial efficacy results in the STS101 prescribing information, despite STS101 not achieving statistical significance (p<0.05) versus placebo on study co-primary endpoints at the primary timepoint of two hours post-treatment.

“Further analysis of SUMMIT trial results, input from our legal-regulatory and statistical consultants, and results of recent qualitative and quantitative physician market research, all confirm our view that STS101 has a highly differentiated profile that positions it as the first and only DHE product suitable for broad use by, and with the potential to address the unmet needs of many of, the estimated forty million people in the United States who experience migraine,” stated John Kollins, Satsuma’s President and Chief Executive Officer. “The totality of high-quality evidence from our SUMMIT trial, as well as from our other STS101 clinical trials, clearly indicate STS101 has robust and sustained antimigraine effects, including for subjects and attacks characterized by the presence of symptoms that predict poor response to treatment. We believe the results of our STS101 clinical program will support our planned STS101 NDA filing in Q1 2023 and subsequent approval, with compelling arguments for inclusion of efficacy results from the SUMMIT trial in the STS101 prescribing information.”

Consistent with prior guidance, Satsuma remains on track to submit the STS101 NDA in the first quarter of 2023. In parallel, the Company is working to secure a commercialization partner for STS101.

Updated Investor Presentation

Concurrent with today’s update, Satsuma has made available an updated investor presentation, which can be found in the Events and Presentations section of the company’s Investors website, here.

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.  STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for robust efficacy, and sustained DHE plasma levels over time with low dose-to-dose variability. DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients. However, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring an easy-to-carry and easy-to-use dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.
        
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the “Company”), as well as the Company’s plans, objectives and expectations for its business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about the Company’s expectations regarding the potential safety and efficacy of STS101, the potential results of the ASCEND and SUMMIT trials, the timing of data readouts for ongoing clinical trials, the anticipated timing for a potential STS101 NDA submission, the potential for STS101 to be an important and differentiated acute treatment option, and the expected cash runway of the Company. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of STS101; the results of preclinical and clinical studies may not be predictive of future results; and the risk that the COVID-19 worldwide pandemic may negatively impact the Company’s business, operations, clinical trials or ability to raise capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR AND CORPORATE CONTACTS

:         

Corey Davis, PhD
LifeSci Advisors, LLC
[email protected]

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
[email protected]

^{_____________________
1} From among photophobia, phonophobia or nausea as indicated by subjects immediately prior to treatment with study medication.
²FDA Guidance, Migraine: Developing Drugs for Acute Treatment, February 2018
³Diener et al., Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth Edition, Cephalalgia, 2019
⁴ Survey of ~100 physicians who are high prescribers of migraine therapeutics, approximately half of whom were neurologists and half primary care physicians.